Hypertension is more than a high reading on a blood pressure monitor. When it persists, it can affect the vascular wall, endothelial function, and the workload on the heart. Researchers are therefore studying whether the repeated blood-flow changes produced by EECP cuffs synchronized with the heartbeat may influence vascular function.
During EECP, the leg and hip cuffs inflate sequentially in diastole and empty just before systole begins. This cycle is investigated through indicators such as shear stress on the inner surface of the vessel, nitric oxide bioavailability, endothelin-1 and systemic vascular resistance. This mechanism does not mean that EECP is an alternative to standard hypertension treatment; studies evaluate possible complementary effects.
A study by Biswas et al., published in Cardiology in Review, evaluated 37 studies and 1,504 patients. Eleven studies were included in the quantitative meta-analysis.
In the meta-analysis, the mean change in systolic blood pressure was reported as −7.85 mmHg (95% confidence interval: −9.59 to −6.11), while the mean change in diastolic blood pressure was reported as −3.94 mmHg (95% confidence interval: −5.56 to −2.33).
Limitations: The authors emphasized that larger studies, standardized protocols, and long-term outcome data are still needed. These findings should not be interpreted as definitive treatment results.
In a retrospective comparative study by Ding et al., 120 elderly patients with isolated systolic hypertension and wide pulse pressure were analyzed. The group using amlodipine was compared with the group in which EECP was added to amlodipine treatment.
At the end of the study, systolic blood pressure, pulse pressure, mean arterial pressure, systemic vascular resistance and endothelin-1 were lower in the combined group; Nitric oxide, flow-mediated dilation (FMD), wall shear stress and coronary flow reserve (CFR) were found to be higher.
Study design: This was not a randomized controlled trial; it was a retrospective comparative study based on past records. The result of a single study cannot be generalized to all patients with hypertension.
Endothelium covers the inner surface of the vessels and plays a role in regulating vascular tone. Nitric oxide promotes vascular relaxation; FMD indicates the capacity of the vessel to respond to increased flow by dilating. Systemic vascular resistance is related to the load the heart encounters when pumping blood into the circulation. CFR refers to the capacity of the coronary circulation to increase blood flow when the need increases.
The 2025 review systematically brought together different studies, while the 2026 study focused specifically on a group that was elderly, had isolated systolic hypertension, and wide pulse pressure. However, differences in study protocols, limited long-term data, and the retrospective design of the 2026 study require cautious interpretation of the results.
No. The basis of hypertension treatment is medications planned by the physician, lifestyle adjustments and regular follow-up. Medications can only be changed by the physician monitoring the patient. If EECP is considered, uncontrolled or severe hypertension, comorbidities and medications used should be evaluated before treatment.
These studies provide a scientific basis for better-designed research into the effects of EECP on blood pressure and vascular biology. For a more detailed, patient-focused overview, see Hypertension and EECP, About EECP, Clinical Evidence, and Microvascular Heart Disease.
Sources: Biswas R et al. Cardiology in Review, 2025. PMID: 40310148; DOI: 10.1097/CRD.0000000000000933. Ding M et al. Pak J Pharm Sci. 2026;39(7):2153–2164. PMID: 42170980; DOI: 10.36721/PJPS.2026.39.7.203.1.
Notes: This content is for general informational purposes only and is not a substitute for medical advice. EECP is not a replacement for standard hypertension treatment.
Your blood pressure measurements and your current treatment are evaluated together by the physician.